-->

Tag: Immunotherapy for PD-L1 positive tumors

Home / Immunotherapy for PD-L1 positive tumors

Categories

Pembrolizumab is approved by the USFDA for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

On March 19, 2025, the Food and Drug Administration officially approved pembrolizumab (Keytruda, Merck) to be used along with trastuzumab and chemotherapy that includes fluoropyrimidine and platinum f...
immunotherapy-for-pd-l1-positive-tumors

Scan the code